2016 Biomax Symposium: Bringing big and complex data into clinical practice

24 June 2016, Martinsried, Germany.
Biomax announces the 2016 Biomax Symposium on "Bringing Big and Complex Data into Clinical Practice" that will take place in Martinsried (near Munich), Germany. This year's Biomax Symposium focuses on how clinical practice and patient treatment can benefit from big and complex data. It will cover the challenges and requirements that need to be addressed in a clinical setting: from gathering big data, guaranteeing data security in daily practice and fostering feedback between complex clinical data and research, to learning from the data to make better treatment decisions. In a nutshell, the symposium will cover using big and complex data to treat the individual with the knowledge of all.

Biomax has hosted this biennial event since 2012 to facilitate the discussion between clinical management and practitioners, pharma, "Big Data" researchers, health insurance payers, public health and government representatives, funding providers, as well as patient representatives. Through the symposium Biomax hopes to share their own and other experiences in implementing such programs. Past symposia have been a popular forum for these important players to learn from each other and discuss the way forward.

Invited speakers and panel discussion participants are leaders from clinical research, healthcare organizations, international research projects and government. The opening session includes presentations by:

  • Prof. Dr. Emiel Wouters, Department of Respiratory Medicine, University Medical Centre, Maastricht
  • Henning Schneider, CIO at the University Medical Center Hamburg-Eppendorf
  • Prof. Dr. Hans-Werner Mewes, School of Life Sciences, Technische Universität München

The symposium is free of charge.

For further information and to register, please visit:
http://www.biomax.com/symposiums/biomax-symposium-2016/

About Biomax
Biomax Informatics AG is a leader in the development of computational solutions for the life sciences. Biomax provides the BioXM™ Knowledge Management Environment and other computational solutions, including the Viscovery® data-mining technology, for better decision making and knowledge management in biomarker identification, patient stratification and targeted medicine. They help customers generate value by integrating information from proprietary and public resources to enable a knowledge-based approach to developing innovative life science products. Biomax’s worldwide customer community includes medical clinics, research organizations and companies that are successful in drug discovery, diagnostics, fine chemicals, food and plant production and healthcare.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

MSD Innovation Factory is looking for digital solu…

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]